The two companies are working together to detect instances of the more contagious B.1.1.7 variant in the U.S. After Colorado identified the first case in the U.S. on Dec. 28, more than 60 cases have since been found across the country.
The agency granted an emergency use authorization to the company for its test, which is meant to detect antibodies against SARS-CoV-2 in the blood. However, antibody testing has both advantages and disadvantages relative to the more common PCR assays.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.